| This week's sponsor is Premier Research. | | | Studying an Addiction Drug? Some Practical Tips To Help
Developing drugs to treat addiction is a complex challenge, and sponsors benefit when they know how addiction trials work. Read our white paper for a closer look. Premier Research. It's what we do. Best. |
Today's Rundown Bayer pays $400M upfront to buy into Loxo cancer drugs Denali, Odonate seek $273M Nasdaq IPOs Locus raises $19M to take CRISPR-based antimicrobial ‘Pac-Man’ into clinic [Sponsored] Looking Toward Abuse Deterrent Opioids Flagship cancer startup Torque gets $25M, Rhythm founder as CEO Seres teams with cancer heavyweights for microbiome-checkpoint inhibitor combination trial MIT scientists propose a safer way to edit genes with CRISPR Featured Story | | | Tuesday, November 14, 2017 Bayer has paid $400 million (€340 million) and committed to more than $1 billion more to buy into Loxo Oncology’s tropomyosin receptor kinase inhibitor franchise. The agreement puts Bayer in charge of global commercialization of a drug that chalked up a 75% response rate in a midphase trial. |
|
|
| This week's sponsor is Deloitte. | | | |
Top Stories Tuesday, November 14, 2017 The heavily backed neurodegenerative diseases biotech Denali Therapeutics and oral chemotherapy biotech Odonate Therapeutics are looking to make hay while the sun shines by filing for two big IPOs. Tuesday, November 14, 2017 North Carolina-based biotech Locus Biosciences is moving ahead with a first clinical trial for its CRISPR-based antimicrobial drugs—armed with $19 million in series A funding. Monday, November 13, 2017 The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results for patients. Tuesday, November 14, 2017 Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer. Tuesday, November 14, 2017 Seres Therapeutics has formed a collaboration to test microbiome therapy SER-401 in combination with an anti-PD-1 checkpoint inhibitor. The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center. Monday, November 13, 2017 CRISPR-Cas9 has generated excitement for its potential use in eliminating disease-causing irregularities in DNA, but most systems rely on viral vectors. Scientists at MIT have developed nanoparticles that could eliminate the need to use viruses to edit genes. | This week's sponsor is Charles River. | | | |
Resources Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. BioBasics: Biotech for the Non-Scientist November 30-December 1, 2017 | Boston, MA CBI’s Commercial Data Insights 2017 November 28-29, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA Register Today – ISPE Biopharmaceutical Manufacturing Conference December 4th-6th, 2017 | San Francisco, CA BIO Asia International Conference March 19-20, 2018 | Tokyo, Japan Molecular Med Tri-Conference February 11-16, 2018 | San Francisco, CA | 